Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.07 EPS

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.07), FiscalAI reports. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million.

Corcept Therapeutics Stock Up 3.2%

NASDAQ CORT traded up $1.14 during trading hours on Tuesday, reaching $36.48. 1,925,894 shares of the company’s stock traded hands, compared to its average volume of 2,360,539. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. The firm has a 50-day simple moving average of $48.10 and a 200 day simple moving average of $66.70. The firm has a market cap of $3.84 billion, a PE ratio of 41.46 and a beta of 0.25.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the sale, the insider owned 1,235 shares in the company, valued at $50,474.45. This represents a 94.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the transaction, the chief executive officer directly owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This trade represents a 1.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 125,000 shares of company stock worth $8,301,450 over the last three months. Company insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in shares of Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after acquiring an additional 1,274,215 shares during the period. UBS Group AG boosted its holdings in Corcept Therapeutics by 413.8% in the third quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock worth $45,705,000 after purchasing an additional 442,898 shares during the last quarter. Morgan Stanley grew its position in Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock worth $55,404,000 after purchasing an additional 405,081 shares during the period. HRT Financial LP purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at $14,753,000. Finally, Tang Capital Management LLC purchased a new stake in Corcept Therapeutics during the 4th quarter valued at $5,455,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. UBS Group initiated coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a report on Wednesday, December 31st. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research note on Wednesday, December 31st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $77.17.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Q4/earnings preview and upcoming results that could reframe near-term expectations for revenue and guidance; earnings coverage may drive short-term trading around the report. 7CORT : Corcept Therapeutics Earnings Preview
• Negative Sentiment: Robbins Geller announced investor deadline notices tied to a class action that alleges Corcept failed to disclose FDA concerns about the adequacy of evidence supporting the relacorilant NDA — this amplifies potential litigation exposure and reputational risk. INVESTOR DEADLINE: Robbins Geller Announcement
• Negative Sentiment: Hagens Berman and multiple other firms (Rosen, Kahn Swick, Bragar, Gainey McKenna & Egleston, Kirby McInerney) have filed or are soliciting lead plaintiffs in securities class actions alleging Corcept ignored repeated FDA warnings about filing the relacorilant NDA — the allegations follow a prior ~50% stock plunge and could lead to costly litigation, settlements, or distraction for management. Example notice: Hagens Berman. Hagens Berman Alert
• Negative Sentiment: Kaplan Fox has notified investors of an investigation into Corcept — an enforcement or discovery-driven inquiry increases downside risk if it expands beyond civil securities claims. Kaplan Fox Investigation Notice
• Negative Sentiment: HC Wainwright cut its price target to $67, signaling analyst skepticism on near-term outlook; analyst downgrades can weigh on sentiment and reduce buy-side conviction while litigation risk is unresolved. HC Wainwright Price Target Cut

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.